Cohanzick Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Cohanzick Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-500	Closed	-$8.2K	–	131
2022 Q4	$8.2K	Hold	500	–	–	﹤0.01%	187
2022 Q3	$9K	Sell	500 -1,500	-75%	-$23.5K	﹤0.01%	277
2022 Q2	$26K	Hold	2,000	–	–	0.01%	295
2022 Q1	$19K	Hold	2,000	–	–	﹤0.01%	386
2021 Q4	$19.5K	Sell	2,000 -3,000	-60%	-$56.4K	﹤0.01%	389
2021 Q3	$170K	Hold	5,000	–	–	0.04%	148
2021 Q2	$183K	Buy	5,000 +1,000	+25%	+$38.7K	0.06%	123
2021 Q1	$179K	Buy	4,000 +2,000	+100%	+$93.1K	0.11%	83
2020 Q4	$114K	Buy	+2,000	New	+$119K	0.09%	58

Other funds holding DCPH

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cohanzick Management's DCPH Position: Q1 2023 in Review

Cohanzick Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2023, closing a stake of 500 shares — an estimated $8.2K sold.

Cohanzick Management first reported a position in DCPH in Q4 2020 and held it in 9 quarters. The position peaked at $183K in Q2 2021. 146 funds tracked by Wall St. Rank hold DCPH as of Q1 2023.

Cohanzick Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Cohanzick Management sold 500 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $8.2K.
Cohanzick Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
Cohanzick Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $183K in Q2 2021.
146 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Cohanzick Management's 13F filing for Q1 2023, filed 12 May 2023.